Real-World Eculizumab Dosing Patterns Among Patients with Paroxysmal Nocturnal Hemoglobinuria in a US Population

References

• Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2014;124(18):2804–2811. doi:10.1182/blood-2014-02-522128
   PubMed Web of Science ®Google Scholar
• Jalbert JJ, Chaudhari U, Zhang H, Weyne J, Shammo JM. Epidemiology of PNH and real-world treatment patterns following an incident PNH diagnosis in the US. Blood. 2019;134(Supplement_1):3407. doi:10.1182/blood-2019-125867
   Web of Science ®Google Scholar
• Canadian Association of PNH Patients. The guide to living well with PNH. 2018. Available from: https://pnhca.org/the-guide-to-living-well-with-pnh. Accessed October 26, 2020.
   Google Scholar
• Hill A, DeZern AE, Kinoshita T, Brodsky RA. Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers. 2017;3:17028. doi:10.1038/nrdp.2017.28
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Highlights of prescribing information: SOLIRIS® (eculizumab); 2019:1–9. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125166s172lbl.pdf. Accessed October 26, 2020.
   Google Scholar
• European Medicines Agency. Soliris - summary of product characteristics. 2009. Available from: https://www.ema.europa.eu/en/documents/product-information/soliris-epar-product-information_en.pdf. Accessed October 26, 2020.
   Google Scholar
• Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111(4):1840–1847. doi:10.1182/blood-2007-06-094136
   PubMed Web of Science ®Google Scholar
• Hill A, Hillmen P, Richards SJ, et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood. 2005;106(7):2559–2565. doi:10.1182/blood-2005-02-0564
   PubMed Web of Science ®Google Scholar
• Hillmen P, Elebute M, Kelly R, et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2010;85(8):553–559. doi:10.1002/ajh.21757
   PubMed Web of Science ®Google Scholar
• Hillmen P, Muus P, Duhrsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007;110(12):4123–4128. doi:10.1182/blood-2007-06-095646
   PubMed Web of Science ®Google Scholar
• Hillmen P, Muus P, Röth A, et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2013;162(1):62–73. doi:10.1111/bjh.12347
   PubMed Web of Science ®Google Scholar
• Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355(12):1233–1243. doi:10.1056/NEJMoa061648
   PubMed Web of Science ®Google Scholar
• DeZern AE, Dorr D, Brodsky RA. Predictors of hemoglobin response to eculizumab therapy in paroxysmal nocturnal hemoglobinuria. Eur J Haematol. 2013;90(1):16–24. doi:10.1111/ejh.12021
   PubMed Web of Science ®Google Scholar
• Kelly R, Arnold L, Richards S, et al. Modification of the eculizumab dose to successfully manage intravascular breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;112(11):3441. doi:10.1182/blood.V112.11.3441.3441
   Web of Science ®Google Scholar
• Kulasekararaj AG, Hill A, Rottinghaus ST, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood. 2019;133(6):540–549. doi:10.1182/blood-2018-09-876805
   PubMed Web of Science ®Google Scholar
• Röth A, Dührsen U. Treatment of paroxysmal nocturnal hemoglobinuria in the era of eculizumab. Eur J Haematol. 2011;87(6):473–479. doi:10.1111/j.1600-0609.2011.01701.x
   PubMed Web of Science ®Google Scholar
• Röth A, Rottinghaus ST, Hill A, et al. Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies. Blood Adv. 2018;2(17):2176–2185. doi:10.1182/bloodadvances.2018020644
   PubMed Web of Science ®Google Scholar
• Füreder W, Valent P. Switching from high-dose eculizumab to ravulizumab in paroxysmal nocturnal hemoglobinuria: a case report. HemaSphere. 2020;4(4):e455. doi:10.1097/HS9.0000000000000455
   PubMed Web of Science ®Google Scholar
• Risitano AM, Marotta S, Ricci P, et al. Anti-complement treatment for paroxysmal nocturnal hemoglobinuria: time for proximal complement inhibition? A position paper from the SAAWP of the EBMT. Front Immunol. 2019;10:1157. doi:10.3389/fimmu.2019.01157
   PubMed Web of Science ®Google Scholar
• Al-Ani F, Chin-Yee I, Lazo-Langner A. Eculizumab in the management of paroxysmal nocturnal hemoglobinuria: patient selection and special considerations. Ther Clin Risk Manag. 2016;12:1161–1170. doi:10.2147/TCRM.S96720
   PubMed Web of Science ®Google Scholar
• Wijnsma KL, Ter Heine R, Moes D, et al. Pharmacology, pharmacokinetics and pharmacodynamics of eculizumab, and possibilities for an individualized approach to eculizumab. Clin Pharmacokinet. 2019;58(7):859–874. doi:10.1007/s40262-019-00742-8
   PubMed Web of Science ®Google Scholar
• Griffin M, Munir T. Management of thrombosis in paroxysmal nocturnal hemoglobinuria: a clinician’s guide. Ther Adv Hematol. 2017;8(3):119–126. doi:10.1177/2040620716681748
   PubMed Web of Science ®Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139. doi:10.1097/01.mlr.0000182534.19832.83
   PubMed Web of Science ®Google Scholar
• Lee JW, Sicre de Fontbrune F, Wong Lee Lee L. Sicre de Fontbrune F, Wong Lee Lee Let al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019;133(6):530–539. doi:10.1182/blood-2018-09-876136
   PubMed Web of Science ®Google Scholar
• Nakayama H, Usuki K, Echizen H, Ogawa R, Orii T. Eculizumab dosing intervals longer than 17 days may be associated with greater risk of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria. Biol Pharm Bull. 2016;39(2):285–288. doi:10.1248/bpb.b15-00703
   PubMed Web of Science ®Google Scholar
• Schrezenmeier H, Röth A, Araten DJ, et al. Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the international PNH registry. Ann Hematol. 2020;99(7):1505–1514. doi:10.1007/s00277-020-04052-z
   PubMed Web of Science ®Google Scholar
• Ricklin D, Mastellos DC, Reis ES, Lambris JD. The renaissance of complement therapeutics. Nat Rev Nephrol. 2018;14(1):26–47. doi:10.1038/nrneph.2017.156
   PubMed Web of Science ®Google Scholar
• Cheng WY, Sarda SP, Mody-Patel N, et al. Real-World Healthcare Resource Utilization (HRU) and costs of patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) receiving eculizumab in a US population. Adv Ther. 2021;38(8):4461–4479. doi:10.1007/s12325-021-01825-4
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Highlights of prescribing information: ULTOMIRIS ™ (ravulizumab-cwvz); 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761108s000lbl.pdf. Accessed February 17, 2022.
   Google Scholar
• Brodsky RA, Peffault de Latour R, Rottinghaus ST, et al. Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria. Haematologica. 2021;106(1):230–237. doi:10.3324/haematol.2019.236877
   PubMed Web of Science ®Google Scholar
• Schrezenmeier H, Kulasekararaj A, Mitchell L, et al. One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naive to complement inhibitor therapy: open-label extension of a randomized study. Ther Adv Hematol. 2020;11:2040620720966137. doi:10.1177/2040620720966137
   Web of Science ®Google Scholar
• US Food and Drug Administration. Highlights of prescribing information: EMPAVELI™ (pegcetacoplan). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215014s000lbl.pdf. Accessed February 17, 2022.
   Google Scholar